The Face-Name Associative Memory Exam (FNAME) is a paired associative memory test created to detect memory deficits in individuals with preclinical Alzheimer's disease (AD). Worse performance on FNAME in cognitively healthy individuals were found related to higher amyloid beta (Aβ) burden measured with Positron-Emission-Tomography using 11 C-PiB (PiB-PET). We previously reported normative data of a Spanish version of FNAME (S-FNAME) in cognitively healthy Spanish-speaking subjects. The aim of the present study was to determine whether performance on S-FNAME was associated with Aβ burden in subjective cognitive decline (SCD) individuals. 200 SCD subjects received neurological and neuropsychological assessments, including the S-FNAME and the Word List task from the Wechsler-Memory-Scale-III (WMS-III). Moreover, they received an MRI and (18)F-Florbetaben Positron-Emission-Tomography (FBB-PET) to measure Aβ burden. Three cognitive factor composites were derived for the episodic memory measures (face-name [SFN-N], face-occupation [SFN-O] and WMS-III) to determine whether episodic memory performance was related to Aβ deposition. Higher global Aβ deposition was significantly related to worse performance on SFN-N but not with SFN-O or WMS-III Composite. Moreover, worse SFN-N performance was significantly related to higher Aβ deposition in bilateral Posterior Cingulate Cortex. The S-FNAME may be a promising neuropsychological tool for detecting SCD individuals with preclinical AD.Alzheimer's disease (AD) is a major health problem with an estimated 50 million people worldwide living with dementia 1,2 with 33% of clinically normal older individuals having the underlying pathology of AD. With the advent of AD prevention trials, there is a growing interest in developing new diagnostic tools to detect the first symptoms of AD that may precede mild cognitive impairment (MCI).Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD dementia 3,4 . It refers to the perception of memory or other cognitive problems without impairment on standardized cognitive tests. Longitudinal studies have demonstrated that cognitively healthy individuals with SCD have a [9][10][11][12] . Preclinical AD, by definition, is the identification of those clinically normal individuals with AD pathological burden. However, preclinical AD cannot be diagnosed with current standard neuropsychological tools and its diagnosis relies on the positivity of the different biomarkers of AD 13 . For this reason, there is an increasing interest in developing neuropsychological tools capable of identifying the subtle cognitive deficits present in the preclinical stage of AD 14 . The Face-Name Associative Memory Exam (FNAME), developed by Rentz and colleagues 15 , is a highly demanding face-name associative memory exam, but easy to administer and found useful for detecting evidence of amyloid-β (Aβ) burden related memory impairment in cognitively healthy individuals. The authors reported that lower performance on the FNAME were rela...